Literature DB >> 35013943

Predictive value of surveillance cultures for bacteremia caused by extended-spectrum beta-lactamase (ESBL)-producing Enterobacterales among patients with hematological diseases.

Takuya Hattori1, Tatsunori Goto2, Masahide Osaki2, Yukiyasu Ozawa2, Koichi Miyamura2.   

Abstract

PURPOSE: Due to the increasing prevalence of extended-spectrum beta-lactamase (ESBL)-producing Enterobacterales, empirical therapies with cefepime or piperacillin/tazobactam for hematology patients with febrile neutropenia have become ineffective. Carbapenems should be administered as soon as possible in such patients with ESBL bacteremia. If the surveillance culture results are consistent with the blood culture findings, the time to adequate treatment initiation can be shortened.
METHODS: All consecutive patients with Enterobacterales bacteraemia who were admitted from January 2013 to December 2018 at the hematology wards were enrolled in this study. Surveillance rectal swab and blood culture results were compared.
RESULTS: In total, 67 patients with Enterobacterales bacteremia underwent surveillance culture prior to the onset of infection. Regarding the presence or absence of ESBL-producing Enterobacterales, 64 (95.5%) patients had surveillance results concordant with blood culture results. The positive predictive value of surveillance culture for bacteremia caused by ESBL-producing Enterobacterales was 95.0%. Moreover, the negative predictive value of surveillance culture for bacteremia caused by non-ESBL-producing Enterobacterales was 95.7%.
CONCLUSION: The concordance rate between the surveillance rectal swab and blood cultures was highly acceptable. Surveillance rectal swab cultures are useful for identifying patients at high risk for ESBL bacteremia.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.

Entities:  

Keywords:  Antimicrobial stewardship; Blood culture; Enterobacterales bacteremia; Extended-spectrum beta-lactamase; Surveillance culture

Mesh:

Substances:

Year:  2022        PMID: 35013943     DOI: 10.1007/s15010-021-01753-z

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  32 in total

1.  Carbapenem versus Cefepime or Piperacillin-Tazobactam for Empiric Treatment of Bacteremia Due to Extended-Spectrum-β-Lactamase-Producing Escherichia coli in Patients with Hematologic Malignancy.

Authors:  Grace E Benanti; Anne Rain T Brown; Terri Lynn Shigle; Jeffrey J Tarrand; Micah M Bhatti; Patrick M McDaneld; Samuel A Shelburne; Samuel L Aitken
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

2.  A 55-Year-Old Immunocompetent Man With Chest Discomfort and Night Sweats.

Authors:  Jiansong Ji; Tiemin Wei; Chenying Lu; Zufei Wang; Shubha Deep Roy; Rakesh Ponnapureddy; Kan Liu
Journal:  Chest       Date:  2020-12       Impact factor: 9.410

Review 3.  The Microbiota in Hematologic Malignancies.

Authors:  Yajing Song; Bryan Himmel; Lars Öhrmalm; Peter Gyarmati
Journal:  Curr Treat Options Oncol       Date:  2020-01-11

4.  Institutional control measures to curtail the epidemic spread of carbapenem-resistant Klebsiella pneumoniae: a 4-year perspective.

Authors:  Matan J Cohen; Colin Block; Phillip D Levin; Carmela Schwartz; Ilana Gross; Yuval Weiss; Allon E Moses; Shmuel Benenson
Journal:  Infect Control Hosp Epidemiol       Date:  2011-07       Impact factor: 3.254

5.  Bloodstream infections with gram-negative organisms and the impact of multidrug resistance in patients with hematological malignancies.

Authors:  Sebastian Scheich; Sarah Weber; Claudia Reinheimer; Thomas A Wichelhaus; Michael Hogardt; Volkhard A J Kempf; Johanna Kessel; Hubert Serve; Björn Steffen
Journal:  Ann Hematol       Date:  2018-07-04       Impact factor: 3.673

6.  Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america.

Authors:  Alison G Freifeld; Eric J Bow; Kent A Sepkowitz; Michael J Boeckh; James I Ito; Craig A Mullen; Issam I Raad; Kenneth V Rolston; Jo-Anne H Young; John R Wingard
Journal:  Clin Infect Dis       Date:  2011-02-15       Impact factor: 9.079

7.  Low-dose Gentamicin for Uncomplicated Enterococcus faecalis Bacteremia May be Nephrotoxic in Children.

Authors:  Sarai Little Ibrahim; Long Zhang; Tammy M Brady; Alice J Hsu; Sara E Cosgrove; Pranita D Tamma
Journal:  Clin Infect Dis       Date:  2015-06-16       Impact factor: 9.079

8.  Factors associated with bacteraemia in febrile, granulocytopenic cancer patients. The International Antimicrobial Therapy Cooperative Group (IATCG) of the European Organization for Research and Treatment of Cancer (EORTC).

Authors:  C Viscoli; P Bruzzi; E Castagnola; L Boni; T Calandra; H Gaya; F Meunier; R Feld; S Zinner; J Klastersky
Journal:  Eur J Cancer       Date:  1994       Impact factor: 9.162

9.  Founder effects in two predominant intronic mutations of UNC13D, c.118-308C>T and c.754-1G>C underlie the unusual predominance of type 3 familial hemophagocytic lymphohistiocytosis (FHL3) in Korea.

Authors:  Ja Young Seo; Joon-Sup Song; Ki-O Lee; Hong-Hee Won; Jong-Won Kim; Sun-Hee Kim; Soo-Hyun Lee; Keon-Hee Yoo; Ki-Woong Sung; Hong Hoe Koo; Hyoung Jin Kang; Hee Young Shin; Hyo-Seop Ahn; Dong Kyun Han; Hoon Kook; Tai Ju Hwang; Chuhl-Joo Lyu; Mi-Jung Lee; Ji-Yoon Kim; Sung-Shik Park; Young-Tak Lim; Bo-Eun Kim; Kyung-Nam Koh; Ho Joon Im; Jong Jin Seo; Hee-Jin Kim
Journal:  Ann Hematol       Date:  2012-11-24       Impact factor: 3.673

10.  Incidence, risk factors, and outcome of bloodstream infections during the pre-engraftment phase in 521 allogeneic hematopoietic stem cell transplantations.

Authors:  O Blennow; P Ljungman; E Sparrelid; J Mattsson; M Remberger
Journal:  Transpl Infect Dis       Date:  2013-12-30       Impact factor: 2.228

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.